🔴 Iovance Biotherapeutics is trading 4.1% down in pre-market after updated results showed a lower response rate

Iovance Biotherapeutics is trading 4.1% lower at $9.17 in pre-market after updated lung cancer results showed a 24.6% overall response rate, versus 25.6% previously reported.

• October 29 Phase 2 results covered 69 patients; the retrospective biomarker-defined subgroup response rate was 59.1%.
• Shares fell 35.45% at the October 29 close, then declined further pre-market; coverage linked the selloff to results.
• Results support a planned 2027 supplemental filing, the company says; no separate October 30 announcement was identified.